Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Current Drug Metabolism
Title:Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Volume: 15 Issue: 2
Author(s): Vojtech Huser, Samuel G. Johnson, Marc S. Williams, Mary V. Relling, Dan Roden, C. Michael Stein, Rachel F. Tyndale, Jesse J. Swen, Mia Wadelius, Stuart A. Scott, Kristine R. Crews, Otito F. Iwuchukwu, Ming Ta Michael Lee, Kelly E. Caudle, Robert R. Freimuth, Jose A.G. Agundez, Matthias Schwab, Caroline F. Thorn, Katrin Sangkuhl, Ellen M. McDonagh, Li Gong, Michelle Whirl-Carrillo, Daniel J. Muller, James M. Hoffman and Teri E. Klein
Affiliation:
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Export Options
About this article
Cite this article as:
Huser Vojtech, Johnson G. Samuel, Williams S. Marc, Relling V. Mary, Roden Dan, Stein Michael C., Tyndale F. Rachel, Swen J. Jesse, Wadelius Mia, Scott A. Stuart, Crews R. Kristine, Iwuchukwu F. Otito, Michael Lee Ta Ming, Caudle E. Kelly, Freimuth R. Robert, Agundez A.G. Jose, Schwab Matthias, Thorn F. Caroline, Sangkuhl Katrin, McDonagh M. Ellen, Gong Li, Whirl-Carrillo Michelle, Muller J. Daniel, Hoffman M. James and Klein E. Teri, Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process, Current Drug Metabolism 2014; 15 (2) . https://dx.doi.org/10.2174/1389200215666140130124910
DOI https://dx.doi.org/10.2174/1389200215666140130124910 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry Macrophage Infiltration, Lectin-Like Oxidized-LDL Receptor-1, and Monocyte Chemoattractant Protein-1 are reduced by Chronic HMG-CoA Reductase Inhibition
Current Neurovascular Research Non Genomic Modulation of Ligand Gated Ionotropic Receptors by Thyroid Hormones
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Avian Cytokines - An Overview
Current Pharmaceutical Design A Pyridinium-substituted Analog of the TRH-like Tripeptide pGlu-Glu- Pro-NH2 and its Prodrugs as Central Nervous System Agents
Medicinal Chemistry Neuromodulators and Therapeutic Targets in Neuropathic Pain: From Molecules to Man
CNS & Neurological Disorders - Drug Targets Crystallization and Preliminary X-ray Diffraction Analysis of CsaA from P. torridus: A Chaperone Rarely Found in Archaea
Current Chemical Biology Conformations and Biological Activities of Amyloid Beta Peptide 25-35
Current Protein & Peptide Science Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology A Current Review of Cypermethrin-Induced Neurotoxicity and Nigrostriatal Dopaminergic Neurodegeneration
Current Neuropharmacology AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Advanced Vectors for Gene Delivery
Current Drug Therapy Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation
Current Topics in Medicinal Chemistry Animal Models of Narcolepsy
CNS & Neurological Disorders - Drug Targets Neurofibrillary Tangles and Senile Plaques in Alzheimers Brains are Associated with Reduced Capillary Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase
Current Neurovascular Research Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-narrative Review of the Recent Clinical Evidences
Current Drug Targets Association Between Anemia and Dementia: A Nationwide, Populationbased Cohort Study in Taiwan
Current Alzheimer Research Impact of Ondansetron on Withdrawal Signs, Fentanyl Requirement and Pain Relief in Opioid-addicted Patients under General Anesthesia
Current Clinical Pharmacology Protective Effects of Dietary Flavonoids in Diabetic Induced Retinal Neurodegeneration
Current Drug Targets EDITORIAL: New Drugs and New Formulations to Optimize Tailoring Strategies
Current Drug Therapy